Divergent syntheses of novel (-)-goniofufurone mimics with an alkoxymethyl group as the side chain have been accomplished from D-glucose in nine synthetic steps and in overall yields 6.7-8.7 %. Their in vitro antiproliferative activity was evaluated against eight human tumour cell lines as well as a single normal cell line. All analogues demonstrated powerful to good antiproliferative effects toward all malignant cell lines under evaluation. Against the HL-60 cell line, all mimics showed increased activities being 27-to 1604-fold more potent than the lead compound, (-)-goniofufurone. Remarkably, the majority of synthesized analogues displayed higher or similar activity to the commercial antitumour agent doxorubicin (DOX) against A549 cell line. The most potent compound exhibited 196-fold stronger cytotoxicity than DOX in the culture of this cell line.
INTRODUCTION
(-)-Goniofufurone (1) is a synthetic styryl lactone, which represents the opposite enantiomer of naturally occurring (+)-goniofufurone (ent-1, Fig. 1 ). After isolation of (+)-goniofufurone from the stem bark of Gonithalamus giganteus (Annonaceae) 1 in 1990, and the confirmation of the absolute stereochemistry of both 1 and ent-1, 2,3 many syntheses of these compounds with unique and intriguing structures have been published. [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] Both, 1 and ent-1, demonstrated a remarkable antiproliferative activity toward several human tumour cell lines. 19, 20 Synthetic molecule 1 and some of its analogues showed more powerful cytotoxicity than the natural product ent-1 and the corresponding analogues from the (+)-series. 21 Previous studies in our laboratory showed that dephenylated (-)-goniofufurone derivatives bearing an ether group with C 9 -and C 10 -hydrocarbon chains (compounds 6 and 7) exhibited in vitro antitumour activity against several human cancer cell lines. 22 As an extension of this work, herein the synthesis and in vitro antitumour activity of six novel (-)-goniofufurone mimics (3-5 and 8-10) and full experimental details for the preparation of 6 and 7 are reported. The preparation and cytotoxicity of known 23,24 dephenylated (-)-goniofufurone analogue 2 is also disclosed.
EXPERIMENTAL

General procedures
Melting points were determined on a Büchi 510, or on a hot stage microscope Nagema PHMK 05 apparatus and are not corrected. Optical rotations were measured on an Autopol IV (Rudolph Research) automatic polarimeter. The IR spectra were recorded with a FTIR Nexus 670 (Thermo-Nicolet) spectrophotometer. The NMR spectra were recorded on a Bruker AC 250 E or a Bruker Avance III 400 MHz instrument and the chemical shifts are expressed in ppm downfield from tetramethylsilane. Low resolution mass spectra were recorded on a Finnigan-MAT 8230 (CI) mass spectrometer. High-resolution mass spectra were taken on a Micromass LCT KA111 spectrometer or on LTQ OrbitrapXL (Thermo Fisher Scientific Inc., USA) mass spectrometer. TLC was performed on DC Alufolien Kieselgel 60 F 254 (E. Merck). Flash column chromatography was performed using Kieselgel 60 (0.040-0.063 mm, E. Merck). All organic extracts were dried with anhydrous Na 2 SO 4 . Organic solutions were concentrated on a rotary evaporator under diminished pressure at a bath temperature below 35 °C.
Synthetic procedures
General procedure for the synthesis of the intermediates 12-19. To a solution of compound 11 (1 eq) in dry Et 2 O (2 mL) were added Ag 2 O (2.6 eq), AgOTf (0.3 eq) and the corresponding alkyl bromide (3 eq). The mixture was stirred under reflux for 8-32 h (Table I) . After completion of the reaction, which was detected by TLC, the mixture was purified by flash column chromatography (eluents in Table I ). The characterization data for 12-19 are given in the Supplementary material to this paper.
General procedure for the synthesis of the analogues 2-10. A solution of starting compound 11-19 (0.1 mmol) in dry EtOH (2 mL) was hydrogenated over 10 % Pd/C (≈10 % of Pd) at room temperature for 18-24 h (Table II) . After completion of the reaction (TLC), the mixture was purified by flash column chromatography (eluents in Table II ). The characterization data for 2-10 are presented in the Supplementary material.
Cytotoxic activity
Cell cultures. Human myelogenous leukaemia (K562), promyelocytic leukaemia (HL--60), T cell leukaemia (Jurkat), Burkitt's lymphoma (Raji) and ER + breast adenocarcinoma (MCF-7) malignant cells were grown in a suspension in RPMI 1640 nutrient medium, while ER − breast adenocarcinoma (MDA-MB 231), cervix carcinoma (HeLa), lung adenocarcinoma epithelial cells (A549), and normal foetal lung fibroblasts (MRC-5) were cultured as a monolayer in DMEM medium. Both media were supplemented with 10 % of foetal calf serum (FTS, NIVNS) and antibiotics (100 IU mL -1 of penicillin and 100 mg mg -1 of streptomycin). The cell lines were cultured in flasks (Costar, 25 mL) at 37 °C in an atmosphere of 100 % humidity and 5 % of CO 2 (Heraeus). Exponentially growing viable cells were used throughout the assays.
MTT test. 25 Cells were harvested, counted using trypan blue and plated into 96-well microtiter plates (Costar) at the optimal seeding density of 5×10 3 cells per well to assure a logarithmic growth rate throughout the assay period. Viable cells were placed in a volume of 90 μL per well, and preincubated in complete medium at 37 °C for 24 h to allow cell stabilization prior to the addition of the substances. The tested substances, at 10-fold the required final concentration, were added (10 μL well -1 ) to all wells, except for the control ones, and the microplates were incubated for 72 h. The wells containing cells without tested substances were used as controls. MTT solution (10 μL) was added to all wells 3 h before the end of incubation period. MTT was dissolved in medium at 5 mg mL -1 and filtered to sterilize and remove the small amount of insoluble residue present in some batches of MTT. Acidified 2-propanol (100 μL of 0.04 M HCl in 2-propanol) was added to all wells and mixed thoroughly to dissolve the dark blue crystals of formazan. After a few minutes at room temperature, to ensure that all crystals were dissolved, the plates were read on a spectrophotometer plate reader (Multiscan MCC340, Labsystems) at 540 and 690 nm. The wells without cells containing complete medium and MTT acted as blanks.
RESULTS AND DISCUSSION
Chemistry
The syntheses of intermediates 12-19 is presented in Table I . Starting compound 11 was prepared from D-glucose in seven synthetic steps as previously reported. 22 O-Alkylation of alcohol 11 with an excess of hexyl bromide in ether, in the presence of silver(I) oxide and silver(I) triflate as catalysts, gave the expected 7-O-hexyl derivative 12 in 69 % yield (Table I, entry 1). Compound 11 under the similar experimental conditions reacted with different alkyl bromides (C 7 -C 13 ) to afford the corresponding ether derivatives 13-19 in good yields (Table I, in good to excellent yields (Table II, 
In vitro antiproliferative activity
The biological activities of synthesized compounds 2-10 were evaluated by an in vitro cytotoxicity test against a panel of eight human malignant cell lines, including human myelogenous leukaemia (K562), human promyelocytic leukaemia (HL-60), T cell leukaemia (Jurkat), Burkitt's lymphoma (Raji), ER + breast adenocarcinoma (MCF-7), ER − breast adenocarcinoma (MDA-MB 231), cervix carcinoma (HeLa) and lung adenocarcinoma epithelial cells (A549) and against single normal cell line, foetal lung fibroblasts (MRC-5). Cell growth inhibition was evaluated using the standard MTT colorimetric assay after exposure of cells to the test compounds for 72 h. 25 (-)-Goniofufurone (1), analogue 2 and the commercial antitumour agent doxorubicin (DOX) were used as positive controls.
According to the resulting IC 50 values (Table III) , of all cell lines tested, four were sensitive to all of the synthesized analogues 2-10 (K562, HL-60, HeLa and A549). Of the remaining four cell lines, Jurkat and Raji cells were sensitive to eight, while MCF-7 and MDA-MB 231 cell lines were sensitive to seven of nine synthesized analogues.
The most active compound in A549 cell culture is analogue 10 (IC 50 = 0.025 µM) that exhibited 94-and 196-fold higher potency when compared to lead 1 and DOX, respectively. Simultaneously, analogue 10 represents the most active compound described in this paper. All the synthesized analogues exhibited strong antiproliferative effects on K562 cells with IC 50 values in the range of 0.18-8.61 µM. The highest potency against this cell line was recorded after treatment with analogue 8 (IC 50 = 0.18 µM), which is approximately as active as DOX (IC 50 = 0.25 µM), but 16-fold more active than lead 1.
All analogues (2-10) demonstrated powerful to good antiproliferative effects towards HL-60 cells (IC 50 values in the range 0.14-9.97 µM), in contrast to lead 1, which was completely inactive against this cell line. Moreover, all analogues with an alkoxymethyl grou(3-10) showed better antiproliferative effects against the HL-60 cell line than diol 2 (IC 50 = 9.97 µM).
The most active molecule against HL-60 cell line was analogue 5 (IC 50 = = 0.68 µM), which exhibited similar activity as DOX, but was 330-fold more potent than lead 1.
Analogue 3 was the most active compound in the culture of Raji cells that exhibited over 2.5-, 6.5-and 21-fold higher potency than control compounds, DOX, 2 and 1, respectively. All novel ether analogues (3-5 and 8-10) demonstrated 4-(4, IC 50 = 5.98 µM) to 21-fold (3, IC 50 = 1.11 µM) higher activity than lead 1, against Raji cells.
The parent compound 1 showed poor activity (IC 50 = 51.27 µM) against MCF-7 cells, as did the previously synthesized compounds 6 and 7, which were practically inactive to these cells (IC 50 >100 µM and IC 50 = 89.36 µM, respectively). However, all new analogues (3-5 and 8-10) and compound 2 exhibited good cytotoxic effects toward this cell line with IC 50 values in the range 0.34-15.36 µM, being essentially 3-150-fold more active than 1.
The most active compound against the MCF-7 cell line was the ether analogue 5. This molecule exhibited submicromolar cytotoxicity (IC 50 = 0.34 µM) although its potency was slightly lower than the activity of DOX (IC 50 = 0.20 µM).
Lead compound 1 was inactive against HeLa and MDA-MB 231 cells, but all novel analogues and dephenylated analogue 2 showed good (0.56-10.32 µM) to moderate inhibitory activity (7.63-36.47 µM), respectively, against these cell lines.
All the synthesized ether analogues (3-10) as well as lead compound 1, were completely inactive toward normal MRC-5 cells. Only molecule 2 showed low cytotoxicity (IC 50 = 59.88 µM) against this cell line. On the contrary, the commercial antitumour agent DOX exhibited a potent cytotoxicity against this cell line.
SAR analysis
As shown in Table III As is further evident from Table III , the introduction of a hydrophobic group, by O-alkylation of OH-7 in 2, resulted in analogues 3-10 of improved cytotoxicity toward the majority of cell lines under evaluation ( Fig. S-35B of the Supplementary material).
Finally, it was found that the length of the side chain of the analogues is not crucial for antiproliferative activity of the analogues 3-10 (Table III and material) . This is in contrast with previous findings, 22 which suggested that one-or two-carbon homologation of the side chain increases the activity of the resulting homologues against most of the cells tested. However, the results of SAR analysis presented in this work are more reliable because they were conducted on seven pairs of analogues, unlike the previous SAR study that was realized with a lower number of compounds.
CONCLUSIONS
To summarize, nine novel (-)-goniofufurone analogues were designed and synthesized from D-glucose as the starting compound. The newly synthesized molecules were evaluated for their antiproliferative activity against eight human malignant cell lines. Eight of the nine synthesized analogues showed submicromolar anticancer activity against at least one of the tested cell lines and five of them were more potent than DOX (10, IC 50 = 0.025 µM, and 6, IC 50 = 0.92 µM against A549; 7, IC 50 = 0.14 µM, and 5, IC 50 = 0.68 µM against HL-60 and 8, IC 50 = 0.18 µM against K562). SAR analysis showed that the replacement of α-hydroxylbenzyl group in 1 with an alkoxymethyl chain, as well as O-alkylation of OH-7 in 2, may improve the cytotoxicity of the analogues towards the majority of the cell lines under evaluation.
All analogues were devoid of any toxicity against a normal human cell line (MRC-5). It is believed that this approach could be used in the search for novel, more potent and selective antitumour agents derived from lead 1.
SUPPLEMENTARY MATERIAL
Analytical and spectral data, as well as additional experimental data, are available electronically from http://www.shd.org.rs/JSCS/, or from the corresponding author on request.
